A UK research contract template is a pre-negotiated model agreement — MTA, mCTA, MNCA or a Lambert/Brunswick collaboration agreement — chosen by the nature of the relationship between the parties, not by habit. Sending samples calls for a material transfer agreement; an NHS-regulated commercial trial calls for a model Clinical Trial Agreement; charity- or government-funded research uses the MNCA; and multi-party R&D with shared IP uses a Lambert or Brunswick collaboration agreement. Picking the wrong one causes avoidable delay, as UK funders and the NHS expect the correct template used unmodified.
A research contract template UK researchers reach for is not one generic document but one of four distinct families, each governed by a different body with different rules on amendment. This article maps each template to the relationship it was built for.
What counts as a UK research contract template?
A UK research contract template is a standardised legal agreement, published and maintained by a national body (the Health Research Authority, UKRI, or the Association of Research Managers and Administrators), for a specific category of research relationship. The HRA states plainly: “there are several different model agreements, and you should use the one that is most appropriate for your study type and sponsorship arrangements.” Under the National Directive on Commercial Contract Research, HRA and Health and Care Research Wales (HCRW) Approval is typically issued conditionally on using the unmodified template — a waiver is possible only in exceptional circumstances.
- Material Transfer Agreement (MTA) — for transferring biological or physical materials only
- Model Clinical Trial Agreement (mCTA) family — for NHS-regulated commercial and non-interventional studies
- Model Non-Commercial Agreement (MNCA) — for publicly or charity-funded research with no commercial sponsor
- Collaboration agreement (Lambert Toolkit or Brunswick Templates) — for multi-party R&D where intellectual property is shared
Material Transfer Agreements (MTA): moving materials, not money
An MTA governs the transfer of physical or biological materials — tissue, cell lines, reagents, data-carrying media — between organisations, without itself constituting a clinical trial or a funded collaboration. Where an NHS or Health and Social Care (HSC) organisation is involved, the model Material Transfer Agreement published by the HRA is the required unmodified template. Where the transfer is purely between two universities or not-for-profit bodies, the Brunswick Material Transfer Agreement, hosted free by the Association of Research Managers and Administrators (ARMA), is the standard route.
Use an MTA — not a collaboration agreement — whenever the relationship is a one-directional or reciprocal transfer of materials with no joint research programme, no shared funding, and no clinical intervention attached.
Clinical Trial Agreements (mCTA): the NHS-regulated route
An mCTA is the mandatory unmodified contract for a commercial sponsor running a regulated clinical trial at an NHS or HSC site. The family also includes the mCIA (medical devices), ATMP-mCTA (advanced therapy medicinal products), PC-mCTA (primary care) and mNISA (non-interventional commercial studies) — each scoped to a specific trial type.
An updated suite of UK model agreements came into use on 28 April 2026, reflecting changes to the Clinical Trials Regulations that took effect the same day, per HRA and the Clinical Trials Toolkit. New IRAS submissions are expected to use the current versions.
| Template | Used when | Host / steward | Modifiable? |
|---|---|---|---|
| MTA (HRA) | Transferring materials to/from an NHS/HSC organisation | Health Research Authority | No — unmodified use expected |
| Brunswick MTA | Transferring materials between universities/not-for-profits | ARMA | No — off-the-shelf template |
| mCTA / mCIA / ATMP-mCTA / PC-mCTA / mNISA | Commercial or non-interventional trials at NHS/HSC sites | HRA + NIHR | No — mandated under the National Directive on Commercial Contract Research |
| MNCA | Non-commercial, publicly/charity-funded research at NHS/HSC sites | HRA | No — policy expectation of unmodified use |
| Lambert Toolkit collaboration agreements | University-business R&D with shared IP | GOV.UK / UKRI-endorsed | Yes — a decision guide selects from several IP models |
| Brunswick collaboration agreements | University-university or not-for-profit R&D | ARMA | Limited — designed for use largely as published |
MNCA: the template for non-commercial research
The Model Non-Commercial Agreement (MNCA) is the UK-wide template for research at NHS or HSC organisations that is funded by government, charity or academic sources rather than a commercial sponsor. Unlike commercial contract research, there is no equivalent National Directive mandating its use, but the HRA maintains a clear “policy expectation that the appropriate UK template will be used without modification,” and warns that departing from this “may result in prolonged central and participating NHS organisation review.” Administrators searching for an “mnca template” should treat it as the non-commercial counterpart to the mCTA family, not a lighter-touch version of a collaboration agreement.
Collaboration agreements: Lambert Toolkit vs Brunswick Templates
Collaboration agreements apply where two or more organisations jointly conduct research and need to allocate intellectual property, publication rights and liability — a fundamentally different problem from moving materials or running a regulated trial. The Lambert Toolkit, published on GOV.UK and endorsed by UK Research and Innovation (UKRI), is built for university-business collaborations: it offers a decision guide plus seven model agreements for one-to-one projects and four consortium agreements for multi-party collaborations, each reflecting a different approach to IP ownership and exploitation.
Where both parties are universities or similar not-for-profit organisations, the Brunswick Suite of Templates, hosted by ARMA, provides an equivalent academic research collaboration agreement designed to avoid renegotiating IP terms from scratch on every project.
- Choose the Lambert Toolkit when a business is a party and IP exploitation terms need active negotiation
- Choose Brunswick Templates when all parties are universities or not-for-profit research organisations
Choosing the right template by relationship type
The decision is governed by relationship type, not by project size or funding value. Ask three questions in sequence: is anything commercial being run as a clinical trial at an NHS/HSC site (mCTA family); if not, is material simply moving between organisations with no joint programme (MTA); if not, is the research funded non-commercially at an NHS/HSC site (MNCA); and only if none of those apply — a multi-party research collaboration with shared IP — does a Lambert or Brunswick collaboration agreement apply.
Frequently asked questions
What is a model Clinical Trial Agreement (mCTA)?
An mCTA is the HRA-published, NIHR-supported unmodified contract required for commercial, industry-sponsored clinical trials run at NHS or HSC organisations, mandated by the National Directive on Commercial Contract Research alongside sibling templates for devices, ATMPs and primary care.
What is the difference between an MTA and a collaboration agreement?
An MTA covers only the transfer of physical or biological materials between two parties with no joint research programme. A collaboration agreement — Lambert Toolkit or Brunswick — governs a shared research programme with joint intellectual property, publication rights and liability, making it a materially broader and more negotiated document.
What is an MNCA and when is it used?
The MNCA (Model Non-Commercial Agreement) is the UK template used when non-commercially funded research — government, charity or academic — takes place at an NHS or HSC organisation. It mirrors the mCTA’s unmodified-use expectation but applies where no commercial sponsor is involved.
Can I modify a UK model agreement instead of using it unmodified?
Only with a granted waiver, which the HRA warns “is liable to add many months of central negotiation” and “is unlikely to be agreed.” Any proposed modification must be disclosed in the IRAS cover letter with a tracked-change version and a change-by-change rationale.
Implications and what to check next
The practical takeaway is procedural discipline: identify the relationship first, select the corresponding UK template second, and reserve bespoke drafting for the rare case where no UK template exists — a justification that must itself be stated clearly in the IRAS application, since HRA guidance notes this “may expedite the review.” Following the 28 April 2026 regulatory changes, administrators should check the HRA’s model agreements page and the Clinical Trials Toolkit before assuming a previously downloaded template is still current. Institutions building internal contracting guidance should map each incoming request against these four relationship types before a bespoke agreement is drafted — this discipline is what keeps study set-up close to the pre-cleared norm rather than the multi-month waiver-negotiation outlier.
